Literature DB >> 24738532

The impact of patient assistance programs and the 340B Drug Pricing Program on medication cost.

Yelba M Castellon, Shahrzad Bazargan-Hejazi1, Miles Masatsugu, Roberto Contreras.   

Abstract

OBJECTIVES: Patient assistance programs and the 340B Drug Pricing Program promise to improve the financial stability, better serve vulnerable patients, and decrease the burden of cost for uninsured patients. Our objective is to examine the financial impact that PAPs and the 340B Program have on improving medication cost. STUDY
DESIGN: Retrospective analysis of medication dispensary data.
METHODS: Dispensary data for uninsured patients obtaining medications at 2 community health centers were collected from February 1 to February 29, 2012. Uninsured patients were divided into 2 samples: (1) patients receiving PAP medications and (2) patients receiving 340B medications. The main outcome measured was the patient's cost savings. Cost savings were calculated based on the amount a medication would have cost had it been purchased by patients at prices found on Epocrates software (drugstore.com). A paired sample t test model using continuous variables was utilized to calculate confidence intervals.
RESULTS: A total of 1420 PAP and 2772 340B individual medications were dispensed to uninsured patients in February 2012. For patients receiving PAP medications the mean ± standard deviation (SD) for age = 52 ± 10. Average cost was $0.11 (95% CI, $0.04-$0.17) and average savings was $617.36 (95% Cl, $581.32-$653.40). For patients receiving 340B medications the mean ±SD for age = 50 ± 14. Average cost was $11.50 (95% CI, $10.55-$12.45). Average saving was $62.31 (95% CI, $57.99-$66.63).
CONCLUSIONS: PAPs and 340B provide significant medication savings for uninsured patient. More research is needed to establish "best practices" for the successful integration of PAPs.

Entities:  

Mesh:

Year:  2014        PMID: 24738532

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  5 in total

1.  The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.

Authors:  Bobby L Clark; John Hou; Chia-Hung Chou; Elbert S Huang; Rena Conti
Journal:  Health Aff (Millwood)       Date:  2014-11       Impact factor: 6.301

2.  Access and Utilization of Asthma Medications Among Patients Who Receive Care in Federally Qualified Health Centers.

Authors:  Asma M Ali; Anne H Gaglioti; Rebecca H Stone; Natalie D Crawford; Kevin K Dobbin; Lokesh Guglani; Henry N Young
Journal:  J Prim Care Community Health       Date:  2022 Jan-Dec

3.  The Cost of Transplant Immunosuppressant Therapy: Is This Sustainable?

Authors:  Alexandra James; Roslyn B Mannon
Journal:  Curr Transplant Rep       Date:  2015-06-01

4.  The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.

Authors:  Rena M Conti; Peter B Bach
Journal:  Health Aff (Millwood)       Date:  2014-10       Impact factor: 6.301

5.  Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use.

Authors:  Lisandro D Colantonio; Shia T Kent; Meredith L Kilgore; Elizabeth Delzell; Jeffrey R Curtis; George Howard; Monika M Safford; Paul Muntner
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-01-29       Impact factor: 2.890

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.